Lost password ?
<< Back to Equity Research
Mouwasat Medical
MOUWASAT, AGAIN AND AGAIN EXPENSIVE BUT NOT RISKY
Oct 24 - Mouwasat Medical (Sell, Saudi Arabia) has slid by 22.4% in the last three months bringing its YTD performance to -3.13%. The euphoric investors’ enthusiasm toward the stock has likely came to an end. ...
Executive summary
Conflict of Interest
Pages 37
Language English
Publish on October 24, 2023
€ 500
VAT Exl.
You might be also interested by these reports :
Apr 29 PM
Idea Kicker
MOUWASAT MEDICAL, A HEALTHY GROWTH STORY BUT EXPE...
Apr 08 AM
Mouwasat Medical
Target pushed up by strong results
Mar 26 AM
Dallah Healthcare
Target boosted by a strong outlook
Mar 26 AM
Mouwasat Medical
Mouwasat Medical increases its net profit by 10%
FIND A REPORT
CONCEPT
Each company is researched in depth using a structured robust and transparent process.

AlphaMena provides analyses based upon exhaustive and homogeneous information which allows to compare stocks geographically, sector-wise, and by thematic.

The analyses include actuarial as well as off balance-sheet data.
BloombergStarmineFactsetReutersCapital IQ